• Product NameVerinurad
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityVerinurad, also known as RDEA3170, is an organic anion transporter URAT1 (SLC22A12) inhibitor, is being developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of gout and hyperuricaemia.
• Target NameOAT inhibitor
• CAS No. 1352792-74-5
• Calculated MW 348.42
• Formulation C20H16N2O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism
  SMILES:CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
  Pathways:Membrane transporter/Ion channel
  Receptor:URAT1
  Boling pt:
  Melting pt:
  Solubility:DMSO: 10 mM
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Diaz-Torn C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting